Company / Cost of Revenue
AXIM BIOTECHNOLOGIES, INC. Cost of Revenue History
FY2015-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$8.5K
FY2018
5-year range
$8.5K / $154.1K
FY2015-FY2018
Trend
-80.1%
vs FY2017
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $154,130 to $8,511 over the past 2 years.
Based on SEC 10-K filings.
$8,511 in FY2018 with a 3-year CAGR of -44.7%.
Improved from $154,130 to $8,511 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -44.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -44.7%, indicating a declining trend.
- In FY2018, cost of revenue decreased 80.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | - | - |
| FY2022 | - | - |
| FY2018 | $8.5K | -80.1% |
| FY2017 | $42.9K | -72.2% |
| FY2016 | $154.1K | +205.9% |
| FY2015 | $50.4K | - |
| FY2013 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2018 · SEC 10-K · Updated Jun 29, 2026